NCT04988295 2026-02-05MARIPOSA-2Janssen Research & Development, LLCPhase 3 Active not recruiting776 enrolled 13 charts 1 FDA
NCT04487080 2026-02-04MARIPOSAJanssen Research & Development, LLCPhase 3 Active not recruiting1,074 enrolled 13 charts 1 FDA
NCT04248829 2024-12-03Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)Yuhan CorporationPhase 3 Active not recruiting393 enrolled 13 charts